This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Results and side‐effects of treating children with growth hormone after kidney transplantation – a preliminary report
The effect of growth hormone ( GH ) therapy on renal function was investigated in 203 children who had undergone kidney transplantation . In addition , the efficacy of GH in stimulating growth as well as other aspects of safety were assessed . The patients were r and omized to receive either GH , 1 IU/kg/week , administered subcutaneously once daily , or no treatment during the first year ( controls ) . During the second year , all patients received GH . The change in growth velocity and A height SD score during the first year of GH treatment was statistically significant compared with controls ( p < 0.0001 ) . During the second year , those patients who received GH during the first year continued to show an increased rate of growth compared with that during the pretreatment period ; however , the mean growth rate was lower than that in the first year of treatment . The mean change in glomerular filtration rate did not differ between the treated and control groups during the first year of the study . However , acute rejection episodes tended to be more frequent during GH treatment , particularly in those patients who had a history of more than one episode . Close monitoring of renal function is therefore recommended
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .